Literature DB >> 15743794

Functional erythropoietin autocrine loop in melanoma.

Suresh M Kumar1, Geza Acs, Dong Fang, Meenhard Herlyn, David E Elder, Xiaowei Xu.   

Abstract

Although erythropoietin (Epo) is a known stimulator of erythropoiesis, recent evidence suggests that its biological functions are not confined to hematopoietic cells. To elucidate the role of Epo and erythropoietin receptor (EpoR) in melanoma, we examined the expression and function of these proteins in melanocytes and melanoma cells. We found increased expression of Epo in melanoma cells compared to melanocyte in vitro. EpoR was also strongly expressed in all of the melanoma cell lines and two of the three melanocyte cell lines examined. Epo expression was significantly higher in melanoma than in benign nevi as determined by immunohistochemistry. Although melanoma cells secreted Epo in normoxic condition in vitro, hypoxia and CoCl(2) treatment increased Epo secretion. EpoR in melanoma cells was functional, because exogenous Epo increased melanoma resistance to hypoxic stress, pretreatment of melanoma cells with Epo significantly increased resistance to dacarbazine treatment, and Epo increased the phosphorylation of EpoR, RAF, and MEK. In conclusion, we demonstrated constitutive expression of Epo and EpoR as well as autonomous secretion of Epo by melanoma cells, indicating a novel autocrine loop of Epo in melanoma. The results suggest that the autocrine and paracrine functions of Epo might play a role in malignant transformation of melanocytes and in the survival of melanoma cells in hypoxia and other adverse conditions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15743794      PMCID: PMC1602342          DOI: 10.1016/S0002-9440(10)62303-6

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  42 in total

Review 1.  The cellular biology of erythropoietin receptors.

Authors:  Terry Lappin
Journal:  Oncologist       Date:  2003

2.  Breast cancer trial with erythropoietin terminated unexpectedly.

Authors:  Brian Leyland-Jones
Journal:  Lancet Oncol       Date:  2003-08       Impact factor: 41.316

3.  Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture.

Authors:  A Nagai; E Nakagawa; H B Choi; K Hatori; S Kobayashi; S U Kim
Journal:  J Neuropathol Exp Neurol       Date:  2001-04       Impact factor: 3.685

4.  Expression of the erythropoietin receptor by trophoblast cellsin the human placenta.

Authors:  D Fairchild Benyo; K P Conrad
Journal:  Biol Reprod       Date:  1999-04       Impact factor: 4.285

5.  Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress.

Authors:  A L Sirén; M Fratelli; M Brines; C Goemans; S Casagrande; P Lewczuk; S Keenan; C Gleiter; C Pasquali; A Capobianco; T Mennini; R Heumann; A Cerami; H Ehrenreich; P Ghezzi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

6.  Origin and fate of erythropoietin in human milk.

Authors:  S E Juul; Y Zhao; J B Dame; Y Du; A D Hutson; R D Christensen
Journal:  Pediatr Res       Date:  2000-11       Impact factor: 3.756

Review 7.  Investigating hypoxic tumor physiology through gene expression patterns.

Authors:  Nicholas C Denko; Lucrezia A Fontana; Karen M Hudson; Patrick D Sutphin; Soumya Raychaudhuri; Russ Altman; Amato J Giaccia
Journal:  Oncogene       Date:  2003-09-01       Impact factor: 9.867

8.  Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression.

Authors:  Geza Acs; Paul J Zhang; Cindy M McGrath; Peter Acs; John McBroom; Ahmed Mohyeldin; Suzhen Liu; Huasheng Lu; Ajay Verma
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

9.  Expression patterns of erythropoietin and its receptor in the developing midbrain.

Authors:  W Knabe; F Knerlich; S Washausen; T Kietzmann; A L Sirén; G Brunnett; H J Kuhn; H Ehrenreich
Journal:  Anat Embryol (Berl)       Date:  2004-02-10

10.  Expression of erythropoietin by the human placenta.

Authors:  K P Conrad; D F Benyo; A Westerhausen-Larsen; T M Miles
Journal:  FASEB J       Date:  1996-05       Impact factor: 5.191

View more
  22 in total

1.  HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors.

Authors:  Anna Budina-Kolomets; Marie R Webster; Julia I-Ju Leu; Matthew Jennis; Clemens Krepler; Anastasia Guerrini; Andrew V Kossenkov; Wei Xu; Giorgos Karakousis; Lynn Schuchter; Ravi K Amaravadi; Hong Wu; Xiangfan Yin; Qin Liu; Yiling Lu; Gordon B Mills; Xiaowei Xu; Donna L George; Ashani T Weeraratna; Maureen E Murphy
Journal:  Cancer Res       Date:  2016-03-16       Impact factor: 12.701

2.  MicroRNA-9 up-regulates E-cadherin through inhibition of NF-κB1-Snail1 pathway in melanoma.

Authors:  Shujing Liu; Suresh M Kumar; Hezhe Lu; Aihua Liu; Ruifeng Yang; Anitha Pushparajan; Wei Guo; Xiaowei Xu
Journal:  J Pathol       Date:  2011-08-24       Impact factor: 7.996

3.  Core erythropoietin receptor signals for late erythroblast development.

Authors:  Madhu P Menon; Jing Fang; Don M Wojchowski
Journal:  Blood       Date:  2005-12-06       Impact factor: 22.113

Review 4.  Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis.

Authors:  Sheng Gao; Jing-Jing Ma; Cheng Lu
Journal:  Tumour Biol       Date:  2014-01

Review 5.  Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents.

Authors:  Charles L Bennett; Stephen Y Lai; Michael Henke; Sara E Barnato; James O Armitage; Oliver Sartor
Journal:  Arch Intern Med       Date:  2010-09-13

6.  Quantitative comparison of erythropoietin receptor levels in the epithelial versus endothelial fractions of primary breast tumors.

Authors:  Chris P Miller; Nicole Urban; C Anthony Blau
Journal:  Anticancer Res       Date:  2011-04       Impact factor: 2.480

7.  Erythropoietin is involved in angiogenesis in human primary melanoma.

Authors:  Domenico Ribatti; Beatrice Nico; Maria Teresa Perra; Vito Longo; Cristina Maxia; Tiziana Annese; Franca Piras; Daniela Murtas; Paola Sirigu
Journal:  Int J Exp Pathol       Date:  2010-08-27       Impact factor: 1.925

8.  Human skin neural crest progenitor cells are susceptible to BRAF(V600E)-induced transformation.

Authors:  S M Kumar; J Dai; S Li; R Yang; H Yu; K L Nathanson; S Liu; H Zhou; J Guo; X Xu
Journal:  Oncogene       Date:  2013-01-21       Impact factor: 9.867

9.  Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway.

Authors:  Ping Fu; Xiaohong Jiang; Murat O Arcasoy
Journal:  Biochem Biophys Res Commun       Date:  2009-01-06       Impact factor: 3.575

10.  Autocrine/paracrine erythropoietin regulates migration and invasion potential and the stemness of human breast cancer cells.

Authors:  Ke Liang; Songbo Qiu; Yang Lu; Zhen Fan
Journal:  Cancer Biol Ther       Date:  2013-10-22       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.